Preview

Rheumatology Science and Practice

Advanced search

Toxic epidermal necrolysis as a variant of severe skin lesions in systemic lupus erythematosus

https://doi.org/10.14412/1995-4484-2018-785-790

Abstract

Toxic epidermal necrolysis (TEN) has been long believed to be the most severe manifestation of drug allergy. However, cutaneous changes as TEN in systemic lupus erythematosus (SLE) were first described in the late 1970s. As of now, the English-language literature published reports of 30 cases of such lesions in SLE. This paper describes a clinical case of TEN as a direct manifestation of SLE; the positive experience has been first depicted in using not only intravenous immunoglobulin, but also rituximab with a good therapeutic effect in Russian clinical practice.

About the Authors

L. D. Vorobyeva
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation

34A, Kashirskoe Shosse, Moscow 115522.



E. A. Aseeva
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.


S. K. Solovyev
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.


T. A. Belousova
Department of Skin and Venereal Diseases, I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia.
Russian Federation

8, Trubetskaya St., Build. 2, Moscow 119991.



N. E. Lopatina
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.


E. G. Sazhina
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.


G. V. Serikova
V.A. Nasonova Research Institute of Rheumatology.
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522.


References

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-85. doi: 10.1056/NEJM199411103311906

2. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens – Johnson syndrome, toxic epidermal ecrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.

3. Letko E, Papaliodis GN, Daoud YJ, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allerg Asthma Immunol. 2005;94(4):419-36. doi: 10.1016/S1081-1206(10)61112-X

4. Sharma VK, Jerajani HR, Srinivas CR, et al. Proposed IADVL Consensus Guidelines 2006: Management of Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). New Delhi: IADVL's Therapeutic Guidelines Committee; 2008.

5. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens–Johnson syndrome and toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-9. doi: 10.1056/NEJM199512143332404

6. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol. 2005;153(2):241-53. doi: 10.1111/j.1365-2133.2005.06721.x

7. Raj D, Brash DE, Grossman D. Keratinocyte apoptosis in epidermal development and disease. J Investigat Dermatol. 2006;126:243-57. doi: 10.1038/sj.jid.5700008

8. Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens–Johnson syndrome. Arch Dis Child. 2000;83:347-52. doi: 10.1136/adc.83.4.347

9. Harr T, French LE. Toxic epidermal necrolysis and Stevens–Johnson syndrome. Orphan J Rare Dis. 2010;5:39-40. doi: 10.1186/1750-1172-5-39

10. Жерносек ВФ, Дюбкова ТП. Синдром Стивенса–Джонсона – токсический эпидермальный некролиз у детей. Часть I. Определение, этиология, патогенез, клинические проявления, системное лечение. Педиатрическая фармакология. 2011;8(1):30-8 [Zhernosek VF, Dyubkova TP. Stevens-Johnson syndrome – toxic epidermal necrolysis in children. Part I. Definition, etiology, pathogenesis, clinical manifestations, systemic treatment. Pediatricheskaya Farmakologiya. 2011;8(1):30-8 (In Russ.)].

11. Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens–Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527-31. doi: 10.1111/j.1398-9995.2006.01295.x

12. Gilliam JN, Sontheimer RD. Skin manifestations of SLE [Review]. Clin Rheum Dis. 1982;8:207-18.

13. Sontheimer RD. Subacute cutaneous lupus erythematosus. Clin Dermatol. 1985;3:58-68. doi: 10.1016/0738-081X(85)90078-1

14. Lerch M, Mainetti C, Terziroli Beretta-Piccoli B. Current Perspectives on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis. Clin Rev Allerg Immunol. 2017 Nov 29;54(1):147-76. doi: 10.1007/s12016-017-8654-z

15. Gilliam IN. The cutaneous signs of lupus erythematosus. Contin Educ Fam Phys. 1977;6:34-70.

16. Sayag J, Mongin M, Weiller PJ, et al. Toxic epidermic necrolysis in acute disseminated lupus erythematosus. Ann Dermatol Venereol. 1980;107(11):1077-81.

17. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol. 1984;10(6):973-8. doi: 10.1016/S0190-9622(84)80317-5

18. Burge SM, Dawber RP. Stevens–Johnson syndrome and toxic epidermal necrolysis in a patient with systemic lupus erythematosus [letter]. J Am Acad Dermatol. 1985;13:665-6. doi: 10.1016/S0190-9622(85)80447-3

19. Bielsa I, Herrero C, Font J, Mascaro JM. Lupus erythematosus and toxic epidermal necrolysis [letter]. J Am Acad Dermatol. 1987;16(6):1265-7. doi: 10.1016/S0190-9622(87)80031-2

20. Ting W, Stone M, Racila D, et al. Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus and the spectrum of the acute syndrome of apoptotic pan-epidermolysis (ASAP): a case report, concept review and proposal for new classification of lupus erythematosus vesiculobullous skin lesions. Lupus. 2004;13(12):941-50. doi: 10.1191/0961203304lu2037sa

21. Mutasim DF. Severe subacute cutaneous lupus erythematosus presenting with generalized erythroderma and bullae. J Am Acad Dermatol. 2003;48:947-9. doi: 10.1067/mjd.2003.244

22. Kelly JP, Auquier A, Rzany B, et al. An international collaborative casecontrol study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995;48:1099-108. doi: 10.1016/0895-4356(95)00004-N

23. Maldelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: A novel manifestation of lupus? J Am Acad Dermatol. 2003;48:525-9. doi: 10.1067/mjd.2003.107

24. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctivebut immunologically heterogeneous bullous disorder. J Invest Dermatol. 1993;100:285-345. doi: 10.1111/1523-1747.ep12355210

25. Махнева НВ, Давиденко ЕБ, Белецкая ЛВ. О проблеме диагностики и дифференциальной диагностики аутоиммунной пузырчатки. Альманах клинической медицины. 2014;34:9-14 [Makhneva NV, Davidenko EB, Beletskaya LV. On the problem of diagnosis and differential diagnosis of autoimmune pemphigus. Al'manakh Klinicheskoy Meditsiny. 2014;34:9-14 (In Russ.)].

26. Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol. 2000;41(4):234-7. doi: 10.1046/j.1440-0960.2000.00426.x

27. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282:490-3. doi: 10.1126/science.282.5388.490

28. Kazatchkine MD, Kaveri SV. Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747-55. doi: 10.1056/NEJMra993360

29. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding. Int Immunopharmacol. 2006;6:543-9. doi: 10.1016/j.intimp.2005.11.012

30. Fine JD. Management of acquired bullous skin diseases. N Engl J Med. 1995;333(22):1475-84. doi: 10.1056/NEJM199511303332207

31. Roujeau JC, Stern RS. Medical progress: severe adverse cutaneous reactions to drugs. NEJM. 1994;331(19):1272-85. doi: 10.1056/NEJM199411103311906


Review

For citations:


Vorobyeva L.D., Aseeva E.A., Solovyev S.K., Belousova T.A., Lopatina N.E., Sazhina E.G., Serikova G.V. Toxic epidermal necrolysis as a variant of severe skin lesions in systemic lupus erythematosus. Rheumatology Science and Practice. 2018;56(6):785-790. (In Russ.) https://doi.org/10.14412/1995-4484-2018-785-790

Views: 1161


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)